Atomoxetine (Synonyms: Tomoxetine; (R)-Tomoxetine)

Name: Atomoxetine
Brand: MedChemExpress
SKU: HY-107370
Rating: 5.0 (4 reviews)

Art. -Nr.: HY-107370 Reinheit: 98.50%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with K_i values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DA_EX and NE_EX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na⁺ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Atomoxetine Chemische Struktur

CAS. Nr. : 83015-26-3

Größe	Verfügbarkeit	Menge
Oil + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Auf Lager	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Auf Lager	Estimated Time of Arrival: December 31
Oil
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
25 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Auf Lager	Estimated Time of Arrival: December 31
100 mg	Angebot einholen
200 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Other Forms of Atomoxetine:

Atomoxetine-d3 hydrochloride In-stock
Atomoxetine hydrochloride In-stock
(Rac)-Atomoxetine hydrochloride Angebot einholen
(Rac)-Atomoxetine-d₇ hydrochloride Angebot einholen
Atomoxetine-d₇ Angebot einholen
Atomoxetine-d₅ Angebot einholen

4 Publications Citing Use of MCE Atomoxetine

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Sodium Channel Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

Na_v1.1 Na_v1.2 Na_v1.3 Na_v1.4 Na_v1.5 Na_v1.6 Na_v1.7 Na_v1.8 Na_v1.9

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	190 1 Compound: 6	Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
MDCK	IC₅₀	3 1 Compound: 4	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
HEK293	IC₅₀	2.1 3 Compound: 6	Inhibition of human ERG expressed in HEK293 cells by patch-clamp method Inhibition of human ERG expressed in HEK293 cells by patch-clamp method	[PMID: 18954038]
HEK293	IC₅₀	5 1 Compound: 1	Inhibition of norepinephrine uptake at human NET expressed in HEK cells Inhibition of norepinephrine uptake at human NET expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	3100 1 Compound: 6	Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	180 1 Compound: 1	Inhibition of serotonin uptake at human SERT in human HEK293 cells Inhibition of serotonin uptake at human SERT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	5 1 Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	180 1 Compound: 1	Inhibition of serotonin uptake at human SERT expressed in HEK cells Inhibition of serotonin uptake at human SERT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	5.1 1 Compound: 6	Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	5 1 Compound: 1	Inhibition of norepinephrine uptake at human NET in human HEK293 cells Inhibition of norepinephrine uptake at human NET in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	5 1 Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET transfected in HEK cells Inhibition of norepinephrine uptake at human NET transfected in HEK cells	[PMID: 18954981]
HeLa	IC₅₀	100 3 Compound: Atomoxetine	Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay	[PMID: 25581017]
HEK293	IC₅₀	180 1 Compound: atomoxetine	Inhibition of serotonin uptake at human SERT expressed in HEK293 cells Inhibition of serotonin uptake at human SERT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	180 1 Compound: atomoxetine	Inhibition of serotonin uptake at human SERT transfected in HEK cells Inhibition of serotonin uptake at human SERT transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	5.1 1 Compound: 6	Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	3 3 Compound: 1	Inhibition of dopamine uptake at human DAT expressed in HEK cells Inhibition of dopamine uptake at human DAT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	190 1 Compound: 6	Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	3 3 Compound: atomoxetine	Inhibition of dopamine uptake at human DAT expressed in HEK293 cells Inhibition of dopamine uptake at human DAT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	2.1 3 Compound: 6	Inhibition of human ERG expressed in HEK293 cells by patch-clamp method Inhibition of human ERG expressed in HEK293 cells by patch-clamp method	[PMID: 18954038]
HEK293	IC₅₀	3 3 Compound: 1	Inhibition of dopamine uptake at human DAT in human HEK293 cells Inhibition of dopamine uptake at human DAT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	3000 1 Compound: 1	Inhibition of dopamine uptake at human DAT in human HEK293 cells Inhibition of dopamine uptake at human DAT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	3 3 Compound: atomoxetine	Inhibition of dopamine uptake at human DAT transfected in HEK cells Inhibition of dopamine uptake at human DAT transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	3000 1 Compound: 1	Inhibition of dopamine uptake at human DAT expressed in HEK cells Inhibition of dopamine uptake at human DAT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	3000 1 Compound: atomoxetine	Inhibition of dopamine uptake at human DAT expressed in HEK293 cells Inhibition of dopamine uptake at human DAT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	2.1 3 Compound: 6	Inhibition of human ERG expressed in HEK293 cells by patch-clamp method Inhibition of human ERG expressed in HEK293 cells by patch-clamp method	[PMID: 18954038]
HEK293	IC₅₀	>5 3 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	3000 1 Compound: atomoxetine	Inhibition of dopamine uptake at human DAT transfected in HEK cells Inhibition of dopamine uptake at human DAT transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	3100 1 Compound: 6	Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HeLa	IC₅₀	100 3 Compound: Atomoxetine	Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay	[PMID: 25581017]
HEK293	IC₅₀	4186 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells	[PMID: 15225731]
JAR	IC₅₀	48 1 Compound: 2	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 19329313]
HEK293	IC₅₀	4383 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells	[PMID: 15225731]
JAR	IC₅₀	48 1 Compound: 4	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
JAR	IC₅₀	48 1 Compound: 5	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18951020]
HEK293	IC₅₀	5 1 Compound: 1	Inhibition of norepinephrine uptake at human NET in human HEK293 cells Inhibition of norepinephrine uptake at human NET in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	5 1 Compound: 1	Inhibition of norepinephrine uptake at human NET expressed in HEK cells Inhibition of norepinephrine uptake at human NET expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	180 1 Compound: 1	Inhibition of serotonin uptake at human SERT expressed in HEK cells Inhibition of serotonin uptake at human SERT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	180 1 Compound: atomoxetine	Inhibition of serotonin uptake at human SERT expressed in HEK293 cells Inhibition of serotonin uptake at human SERT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	5 1 Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	5 1 Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET transfected in HEK cells Inhibition of norepinephrine uptake at human NET transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	180 1 Compound: 1	Inhibition of serotonin uptake at human SERT in human HEK293 cells Inhibition of serotonin uptake at human SERT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	180 1 Compound: atomoxetine	Inhibition of serotonin uptake at human SERT transfected in HEK cells Inhibition of serotonin uptake at human SERT transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	5.1 1 Compound: 6	Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	190 1 Compound: 6	Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	> 5000 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	> 5000 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	3100 1 Compound: 6	Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	4186 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	4383 1 Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells	[PMID: 15225731]
HeLa	IC₅₀	100 3 Compound: Atomoxetine	Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay	[PMID: 25581017]
JAR	IC₅₀	48 1 Compound: 2	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 19329313]
JAR	IC₅₀	48 1 Compound: 4	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
JAR	IC₅₀	48 1 Compound: 5	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18951020]
MDCK	IC₅₀	3 1 Compound: 4	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]

In Vitro

Atomoxetine (Tomoxetine) (1-100 μM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNa_v1.5) in a state and dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex^[1].
Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats^[1]
Dosage:	0.3, 1 and 3 mg/kg
Administration:	Intraperitoneal injection; for 4 hours
Result:	Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold.

Animal Model:	Spontaneously hypertensive rat (SHR)^[3]
Dosage:	0.1, 0.3, 1.25 and 5.0 mg/kg
Administration:	Intraperitoneal injection and oral administration; for 14 days
Result:	Had non-impact on the measurement of motor activity.

Klinische Studie

Molekulargewicht

255.35

Formel

C₁₇H₂₁NO

CAS. Nr.

83015-26-3

Appearance

Oil

Color

Colorless to light yellow

SMILES

CC(C=CC=C1)=C1O[C@@H](C2=CC=CC=C2)CCNC

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (391.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9162 mL	19.5810 mL	39.1619 mL
5 mM	0.7832 mL	3.9162 mL	7.8324 mL
10 mM	0.3916 mL	1.9581 mL	3.9162 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Reinheit & Dokumentation

Purity: 98.50%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (250 KB) HNMR (139 KB) RP-HPLC (252 KB) LCMS (236 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. [Content Brief]

[2]. Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489. [Content Brief]

[3]. Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9162 mL	19.5810 mL	39.1619 mL	97.9048 mL
	5 mM	0.7832 mL	3.9162 mL	7.8324 mL	19.5810 mL
	10 mM	0.3916 mL	1.9581 mL	3.9162 mL	9.7905 mL
	15 mM	0.2611 mL	1.3054 mL	2.6108 mL	6.5270 mL
	20 mM	0.1958 mL	0.9790 mL	1.9581 mL	4.8952 mL
	25 mM	0.1566 mL	0.7832 mL	1.5665 mL	3.9162 mL
	30 mM	0.1305 mL	0.6527 mL	1.3054 mL	3.2635 mL
	40 mM	0.0979 mL	0.4895 mL	0.9790 mL	2.4476 mL
	50 mM	0.0783 mL	0.3916 mL	0.7832 mL	1.9581 mL
	60 mM	0.0653 mL	0.3263 mL	0.6527 mL	1.6317 mL
	80 mM	0.0490 mL	0.2448 mL	0.4895 mL	1.2238 mL
	100 mM	0.0392 mL	0.1958 mL	0.3916 mL	0.9790 mL

Atomoxetine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Atomoxetine83015-26-3Tomoxetine(R)-TomoxetineSerotonin TransporterSodium Channel5-HTTSERTSLC6A4Na channelsNa+ channelsVGSCsnoradrenalinecatecholaminergicdopamineserotoninInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Produktname			Requested Quantity *
Name des Antragstellers *			Anrede
E-Mail-Addresse *			Telefonnummer *
Department			Name der Organisation *
City			Bundesland
Country or Region *
Bemerkungen

Produktname			Lot #
Name des Antragstellers *			E-Mail-Addresse *
Telefonnummer			Department *
Name der Organisation *			Country or Region *
Bemerkungen

Name
Email *

	Sorry, but the email address you supplied was invalid.

Atomoxetine (Synonyms: Tomoxetine; (R)-Tomoxetine)

Kundenbewertung

Other Forms of Atomoxetine:

Atomoxetine Related Antibodies

4 Publications Citing Use of MCE Atomoxetine

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Sodium Channel Isoform-spezifische Produkte anzeigen:

Biologische Aktivität

Reinheit & Dokumentation

Verweise

Kundenbewertung

Atomoxetine Related Antibodies

Molaritätsrechner

Verdünnungsrechner

Complete Stock Solution Preparation Table

Atomoxetine Related Classifications

Keywords:

Ihre kürzlich angesehenen Produkte:

Kundenbewertung

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report